Observed Signal · Jul 29, 2026 · earnings · Source: SEC API · Impact: 4.2/5
10-Q Financial Filing Analysis for CGI (2026-07-29)
Corcept Therapeutics reported strong financial results for the second quarter ended June 30, 2026, generating net product revenue of $256.1 million, a 31.7% increase year-over-year. Growth was accelerated by the commercial launch of Lifyorli (relacorilant) in combination with nab-paclitaxel for platinum-resistant ovarian cancer, which contributed $47.6 million in debut quarterly sales alongside core hypercortisolism therapies. On the regulatory and legal front, Corcept resubmitted its relacorilant NDA for endogenous Cushing's syndrome with a PDUFA date set for December 17, 2026, while the Court of Appeals affirmed a non-infringement ruling in the Teva patent litigation and denied a rehearing en banc in July 2026.
The filing highlights significant commercial diversification and top-line acceleration via the successful rollout of Lifyorli, alongside critical regulatory timelines for relacorilant and resolution of key patent litigation headwinds.
Track CGI Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Q2 2026 net product revenue rose 31.7% year-over-year to $256.1 million, bolstered by $47.6 million in initial sales from newly launched Lifyorli.
- Corcept resubmitted its New Drug Application (NDA) for relacorilant in endogenous Cushing's syndrome on June 17, 2026, establishing an FDA PDUFA target action date of December 17, 2026.
- The Court of Appeals affirmed a District Court ruling of non-infringement in the Teva patent litigation, with a petition for rehearing en banc denied in July 2026.
Connected Companies & Entities
1 Entity mappedRelated Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
10-Q Financial Filing Analysis for CGI (2026-11-03)
Corcept Therapeutics reported significant financial growth for Q3 2026, driven by expanding commercial execution across its endocrinology franchise and the initial launch ramp of Lifyorli (relacorilant). Net product revenue rose 64.0% year-over-year to $340.5M, supported by $249.1M in hypercortisolism product sales and a $91.4M contribution from Lifyorli following its April 2026 U.S. launch. Operating income surged tenfold to $114.7M from $10.2M in Q3 2025, benefiting from gross margin expansion (cost of sales at just 1.4% of revenue) and disciplined operating expenditure leverage. Net income reached $126.8M, bolstered by a $6.5M net income tax benefit. Corcept maintains a robust balance sheet with $662.3M in cash and marketable securities and no long-term debt, positioning the company securely as it awaits the PDUFA target review date of December 17, 2026, for relacorilant in hypercortisolism.
8-K Financial Filing Analysis for CGI (2026-11-03)
On November 3, 2026, Corcept Therapeutics Incorporated furnished a Form 8-K under Items 2.02 and 7.01 announcing the release of its financial results for the third quarter ended September 30, 2026, along with a corporate update. The detailed financial statements and operational metrics were provided via an accompanying press release attached as Exhibit 99.1. The filing fulfills regulatory disclosure requirements under Regulation FD without formal incorporation into Securities Act registration statements.
10-Q Financial Filing Analysis for Johnson & Johnson (2026-10-21)
Johnson & Johnson reported fiscal Q3 2026 sales to customers of $25.40 billion, up 5.9% year-over-year (6.0% operational growth), driven by double-digit growth in Oncology and steady demand in MedTech, which offset biosimilar erosion from STELARA. However, consolidated net earnings collapsed to $210 million (diluted EPS of $0.09) from $5.15 billion in Q3 2025. This sharp profitability decline was primarily caused by a $5.5 billion pre-tax accrual recorded in Other (income) expense, net for a proposed comprehensive settlement of the talc ovarian cancer litigation, alongside a $1.0 billion in-process R&D charge from the Firefly Bio acquisition and ongoing Orthopaedics separation costs.
Receive all future signals for CGI & competitors in your briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.